Literature DB >> 10624431

Combined phacoemulsification--vitrectomy surgery: technique, indications and outcomes.

M D Leyland1, W E Schulenburg.   

Abstract

PURPOSE AND METHODS: Cataract extraction may be combined with vitrectomy to improve the operative view and/or enhance post-operative rehabilitation. A retrospective review of the records of all patients undergoing combined phacoemulsification and vitrectomy procedures since 1993 was performed. Surgical technique is discussed.
RESULTS: Fifty operations on 49 patients are described. Visual acuity improved overall (mean LogMAR acuity 1.58 +/- 0.74 pre-operatively and 1.17 +/- 0.76 LogMAR post-operatively), with 57% of patients having improved acuity post-operatively. Operative complications were few and post-operative complications were acceptable given the severity of the posterior segment disease.
CONCLUSIONS: Combined phacoemulsification-vitrectomy surgery is a viable option in the management of posterior segment disease in the presence of cataract. It has a number of advantages over other approaches, and can be combined with intraocular lens insertion into the capsular bag in most cases.

Entities:  

Mesh:

Year:  1999        PMID: 10624431     DOI: 10.1038/eye.1999.88

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Presbyopic phacovitrectomy.

Authors:  R Ling; P Simcock; J McCoombes; S Shaw
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

2.  23-gauge vitrectomy and silicone oil tamponade with and without phacoemulsification in rhegmatogenous retinal detachment.

Authors:  Seyhan Sonar Ozkan; Mehmet Citirik; Emrullah Beyazyildiz; Ozlem Beyazyildiz
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  The options to minimize the surgical trauma to treat ocular diabetic complications and to improve postoperative recovery and quality of life require an individualized approach.

Authors:  Wolfgang F Schrader; Tatjana Josifova
Journal:  EPMA J       Date:  2010-03-16       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.